BIIB-028

• Description :

  BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90) . BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation[1][2].

• UNSPSC :

  12352005

• Target :

  HSP

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/biib-028.html

• Smiles :

  CC(C(OC)=C(C)C=N1)=C1CN2C3=NC(N)=NC(Cl)=C3C(C#CCCOP(O)(O)=O)=C2

• Molecular Formula :

  C19H21ClN5O5P

• Molecular Weight :

  465.83

• References & Citations :

  [1]Soga S, et al., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19 (3) :366-76.|[2]Rahimi M N. Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90) : from design and synthesis to cellular drug delivery[D]. UNSW Sydney, 2020.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [911398-13-5]